CN1513542A - 一种治疗病毒性心肌炎的中药制剂及其制备方法 - Google Patents
一种治疗病毒性心肌炎的中药制剂及其制备方法 Download PDFInfo
- Publication number
- CN1513542A CN1513542A CNA2003101239967A CN200310123996A CN1513542A CN 1513542 A CN1513542 A CN 1513542A CN A2003101239967 A CNA2003101239967 A CN A2003101239967A CN 200310123996 A CN200310123996 A CN 200310123996A CN 1513542 A CN1513542 A CN 1513542A
- Authority
- CN
- China
- Prior art keywords
- radix
- chinese medicine
- group
- viral myocarditis
- medicine preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010047470 viral myocarditis Diseases 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims description 59
- 238000000034 method Methods 0.000 title description 16
- 239000003814 drug Substances 0.000 claims abstract description 83
- 238000011282 treatment Methods 0.000 claims description 45
- 239000000843 powder Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000002671 adjuvant Substances 0.000 claims description 7
- 239000012567 medical material Substances 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 240000005373 Panax quinquefolius Species 0.000 abstract description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract description 2
- 238000010298 pulverizing process Methods 0.000 abstract description 2
- 235000018142 Hedysarum alpinum var americanum Nutrition 0.000 abstract 1
- 240000006461 Hedysarum alpinum var. americanum Species 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 30
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 26
- 229930010555 Inosine Natural products 0.000 description 22
- 229960003786 inosine Drugs 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 229940079593 drug Drugs 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 238000002560 therapeutic procedure Methods 0.000 description 15
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 208000009525 Myocarditis Diseases 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 230000000747 cardiac effect Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000003387 muscular Effects 0.000 description 8
- 230000002107 myocardial effect Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 210000004165 myocardium Anatomy 0.000 description 6
- 230000009182 swimming Effects 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 4
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000001467 acupuncture Methods 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 230000001047 pyretic effect Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 230000001502 supplementing effect Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 3
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 210000001630 jejunum Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000000713 mesentery Anatomy 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- GZVMBXDQUQRICT-TZNWHQCUSA-N 3-[(3s,5r,8r,9s,10s,13r,14s)-14-hydroxy-3-[(2s,3r,4r,5r,6s)-3-hydroxy-4-methoxy-6-methyl-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyoxan-2-yl]oxy-10,13-dimethyl-1,2,3,4,5,6, Chemical compound C1([C@@]2(C)CC[C@H]3[C@H]([C@]2(CC1)O)CC[C@H]1[C@]3(C)CC[C@@H](C1)O[C@@H]1[C@H](O)[C@H]([C@@H]([C@H](C)O1)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)OC)C1=CC(=O)OC1 GZVMBXDQUQRICT-TZNWHQCUSA-N 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 229930191001 Thevetin Natural products 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 210000004279 orbit Anatomy 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- XVPBINOPNYFXID-JARXUMMXSA-N 85u4c366qs Chemical compound C([C@@H]1CCC[N@+]2(CCC[C@H]3[C@@H]21)[O-])N1[C@@H]3CCCC1=O XVPBINOPNYFXID-JARXUMMXSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 240000001829 Catharanthus roseus Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 1
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241001092500 Photinia x fraseri Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 208000009729 Ventricular Premature Complexes Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000008862 fructus schizandrae, radix ginseng, radix ophiopogonis drug combination Substances 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 239000005337 ground glass Substances 0.000 description 1
- 239000009912 gualou xiebai baijiutang Substances 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 229930014456 matrine Natural products 0.000 description 1
- 238000011430 maximum method Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 229930015582 oxymatrine Natural products 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000005182 tip of the tongue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000008945 zhigancao decoction Substances 0.000 description 1
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101239967A CN1292766C (zh) | 2002-12-31 | 2003-12-25 | 一种治疗病毒性心肌炎的中药制剂及其制备方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN02159094.X | 2002-12-31 | ||
CN02159094 | 2002-12-31 | ||
CNB2003101239967A CN1292766C (zh) | 2002-12-31 | 2003-12-25 | 一种治疗病毒性心肌炎的中药制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1513542A true CN1513542A (zh) | 2004-07-21 |
CN1292766C CN1292766C (zh) | 2007-01-03 |
Family
ID=34276123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2003101239967A Expired - Fee Related CN1292766C (zh) | 2002-12-31 | 2003-12-25 | 一种治疗病毒性心肌炎的中药制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1292766C (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1327845C (zh) * | 2004-10-19 | 2007-07-25 | 哈尔滨医科大学 | 一种治疗心脑血管病的中药 |
CN101439082B (zh) * | 2007-11-22 | 2012-07-04 | 天津天士力制药股份有限公司 | 一种含苦参提取物的中药颗粒及其制备方法 |
CN102160884B (zh) * | 2010-02-24 | 2012-09-05 | 吕凌燕 | 治疗急性期病毒性心肌炎的中药制剂 |
CN104258082A (zh) * | 2014-10-21 | 2015-01-07 | 万爱玲 | 一种治疗心脾两虚型病毒性心肌炎的中药 |
CN105327197A (zh) * | 2015-12-16 | 2016-02-17 | 朱惠连 | 一种治疗湿热内侵型小儿病毒性心肌炎的中药 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1053815C (zh) * | 1994-03-04 | 2000-06-28 | 李永光 | 治疗病毒性心肌炎的中药 |
CN1124148C (zh) * | 2001-01-21 | 2003-10-15 | 程志清 | 一种治疗病毒性心肌炎的中药及其制剂工艺 |
-
2003
- 2003-12-25 CN CNB2003101239967A patent/CN1292766C/zh not_active Expired - Fee Related
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1327845C (zh) * | 2004-10-19 | 2007-07-25 | 哈尔滨医科大学 | 一种治疗心脑血管病的中药 |
CN101439082B (zh) * | 2007-11-22 | 2012-07-04 | 天津天士力制药股份有限公司 | 一种含苦参提取物的中药颗粒及其制备方法 |
CN102160884B (zh) * | 2010-02-24 | 2012-09-05 | 吕凌燕 | 治疗急性期病毒性心肌炎的中药制剂 |
CN104258082A (zh) * | 2014-10-21 | 2015-01-07 | 万爱玲 | 一种治疗心脾两虚型病毒性心肌炎的中药 |
CN105327197A (zh) * | 2015-12-16 | 2016-02-17 | 朱惠连 | 一种治疗湿热内侵型小儿病毒性心肌炎的中药 |
Also Published As
Publication number | Publication date |
---|---|
CN1292766C (zh) | 2007-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100342889C (zh) | 一种治疗痛风的中药制剂及其制备方法和应用 | |
CN101468154B (zh) | 偏瘫通脉舒络中药制剂 | |
CN1167454C (zh) | 一种通过神阙穴进行排毒的中药组合物及其制备方法 | |
CN1411830A (zh) | 治疗高血压的药物及其制备方法 | |
CN1621080A (zh) | 一种戒除毒瘾的药物及其制备方法 | |
CN108853433A (zh) | 一种治疗糖尿病肾病的中药及其制备方法 | |
CN1292766C (zh) | 一种治疗病毒性心肌炎的中药制剂及其制备方法 | |
CN1232279C (zh) | 一种降血脂的中药 | |
CN1285354C (zh) | 一种治疗脑梗塞的药物 | |
CN1319587C (zh) | 肝脾灵粉 | |
CN1276764C (zh) | 一种中药组合物在制备治疗缺铁性贫血药物中的应用 | |
CN1245197C (zh) | 治疗冠心病、病毒性心肌炎的中药制剂 | |
CN1260973A (zh) | 保健茶枕 | |
CN1173718C (zh) | 一种治疗红斑狼疮免疫疾病所致痹症的药物 | |
CN1309412C (zh) | 一种治疗艾滋病的药物组合物及其制备方法 | |
CN1413727A (zh) | 一种根治艾滋病的药物组合物 | |
CN1126558C (zh) | 一种治疗红斑狼疮所致肾脏损害的药物 | |
CN1063077C (zh) | 一种降血脂的中药药剂及其制法 | |
CN1183933C (zh) | 治疗肾功能不全的药物及其制备方法 | |
CN1269517C (zh) | 抗艾滋病毒口服液 | |
CN101045116A (zh) | 一种治疗胆囊炎的中药药物 | |
CN1413647A (zh) | 一种根治艾滋病的纯中药制剂 | |
CN1323656C (zh) | 一种治疗风湿性关节炎的药物及其喷雾剂的制备工艺 | |
CN1064544C (zh) | 一种治疗肝病的中药肝愈散 | |
CN1616010A (zh) | 一种治疗糖尿病的药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070103 Termination date: 20191225 |